RESULTS OF USING THE MAGGIC HEART FAILURE RISK SCORE AND GALECTIN-3 LEVELS IN ASSESSING MORTALITY RISK IN PATIENTS WITH CHRONIC HEART FAILURE AND RHEUMATOID ARTHRITIS

Background. Chronic autoimmune inflammation in rheumatoid arthritis has a negative impact on the progression of atherosclerosis, morphofunctional parameters of the myocardium, blood pressure, and the risk of mortality in such patients. 
The aim of the study. To perform a comparative analysis of the MAGGIC (Meta-Analysis Global Group in Chronic Heart Failure) score coefficients and galectin-3 levels in patients with chronic heart failure with and without rheumatoid arthritis. 
Materials and methods. We examined 216 patients with heart failure. Two comparable groups were identified: the study group consisted of 100 patients with chronic heart failure and rheumatoid arthritis, the comparison group – of 116 patients with chronic heart failure without rheumatoid arthritis. The analysis of key laboratory and instrumental data and galectin-3 levels was performed. A regression analysis of the associations between the concentration of galectin-3 and the parameters determined using the MAGGIC heart failure risk score was carried out.
Results. The study showed significant statistical differences in the level of galectin-3: in the group of patients with rheumatoid arthritis – 17.4 ± 4.2 ng/ml, in patients without rheumatoid arthritis – 14.3 ± 3.1 ng/ml (p = 0.005). 
The average MAGGIG heart failure risk score in the group of patients with chronic heart failure and rheumatoid arthri-tis was 14 ± 2.1, without rheumatoid arthritis – 12 ± 1.4 (p = 0.01). The risk of mortality during the first year was 7.0 and 4.8 % (p = 0.02), within 3 years – 17.5 and 12.2 % (p = 0.04), respectively. Using regression analysis of interrela-tions of galectin-3 levels with mortality risk identified using the MAGGIC score, a statistically significant association was found (β = –0.04; SD = 10 ± 2.5; r = 0.46; r2 = 0.37; p = 0.002).
Conclusion. Patients with chronic heart failure and rheumatoid arthritis have higher levels of galectin-3 in their blood compared to people without rheumatoid arthritis. In addition, they have an increased risk of death according to the MAGGIC score. A statistically significant association of galectin-3 with the parameters of the MAGGIC heart failure risk score has been revealed.

1. Драпкина О.М., Бойцов С. А., Омельяновский В.В. Социально-экономический ущерб, обусловленный хронической СН, в Российской Федера-ции. Российский кардиологический журнал. 2021;26(6):4490 [Drapkina O.M., Boytsov S.A, Omelyanovsky V.V. Socioe-conomic impact of heart failure in Russia. Russian Journal of Cardiology. 2021;26(6):4490 (In Russian)]. DOI:10.15829/1560-4071-2021-4490

2. Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020; 25(11):4083 [Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020; 25(11):4083 (In Russian)]. DOI:10.15829/1560-4071-2020-4083

3. Chen J., Norling L.V., Cooper D. Cardiac Dysfunction in Rheumatoid Arthritis: The Role of Inflammation. Cells. 2021; 10(4): 881. DOI: 10.3390/cells10040881

4. Анкудинов А.С., Калягин А.Н. Анализ взаимосвязи иммунологических фак-торов и воспалительных маркеров с течением хронической сердечной недостаточности на фоне ревматоидного артрита Кардиология. 2018;58(s10):4-8 [Ankudinov A.S., Kalyagin A.N. Analysis of the re-lationship of immunological factors and inflammatory markers with the course of chronic heart failure against the background of rheumatoid arthritis. Cardiology. 2018; 58 (s10): 4-8 (In Russian)]. DOI: 10.18087/cardio.2495

5. Khalid Y., Dasu N., Shah A. Incidence of congestive heart failure in rheumatoid ar-thritis: a review of literature and meta-regression analysis. ESC Heart Fail. 2020; 7(6): 3745-3753. DOI: 10.1002/ehf2.12947

6. Ferreira M.B., Fonseca T., Costa R. Prevalence, risk factors and proteomic biopro-files associated with heart failure in rheumatoid arthritis: The RA-HF study. Eur J In-tern Med. 2021; 85: 41-49. DOI: 10.1016/j.ejim.2020.11.002

7. Ahlers M.J., Lowery B.D., Farber-Eger E. et al. Heart Failure Risk Associated With Rheumatoid Arthritis-Related Chronic Inflammation. J Am Heart Assoc. 2020; 9(10): e014661. DOI: 10.1161/JAHA.119.014661

8. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42(25):2439-2454. DOI:10.1093/eurheartj/ehab309

9. Mavrogeni S.I., Markousis-Mavrogenis G., Koutsogeorgopoulou L. et al. Patho-physiology and imaging of heart failure in women with autoimmune rheumatic dis-eases. Heart Fail Rev. 2019;24(4):489-498. DOI:10.1007/s10741-019-09779-0

10. Park E., Griffin J., Bathon J.M. Myocardial dysfunction and heart failure in rheu-matoid arthritis. Arthritis Rheumatol. 2022; 74(2):184-199. DOI: 10.1002/art.41979

11. Подзолков В.И., Драгомирецкая Н.А., Казадаева А.В. Галектин-3 как маркер кардиоренального синдрома у больных хронической сердечной недостаточно-стью. Рациональная фармакотерапия в кардиологии. 2022;18(2):153-159 [Pod-zolkov V.I., Dragomiretskaya N.A., Kazadaeva A.V. et al. Galectin-3 is a marker of cardiorenal syndrome in chronic heart failure. Rational pharmacotherapy in cardiolo-gy. 2022;18(2):153-159 (In Russian)]. DOI: 10.20996/1819-6446-2022-04-04

12. Zaborska B., Sikora-Frąc M., Smarż K. The Role of Galectin-3 in Heart Failure-The Diagnostic, Prognostic and Therapeutic Potential-Where Do We Stand? Int J Mol Sci. 2023;24(17):13111. DOI: 10.3390/ijms241713111

13. McDonagh T.A., Metra M., Adamo M. et al. ESC Scientific Document Group. 2021 ESC Guide lines for the diagnosis and treatment of acute and chronic heart fail-ure: Developed by the Task Force for the diagnosis and treatment of acute and chron-ic heart failure of the European Society of Cardiology (ESC). With the special contri-bution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022:24(1):4-131. DOI:10.1093/eurheartj/ehab368.

14. Насонов Е.Л. Ревматология. Клинические рекомендации. М.:ГЭОТАР-Медиа; 2017 [Nasonov E.L. Rheumatology. Clinical recommendations. Mos-cow:GEOTAR-Media; 2017 (In Russian)].

15. Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. М.:МедиаСфера;2002 [Rebrova O.Yu. Statistical analysis of medical data. Application of the STATISTICA application soft-ware package. M.:Mediasphere;2002 (In Russian)].

16. Ларина В.Н., Ойноткинова О.Ш., Лунев В.И. Фенотипы хронической сердечной недостаточности с сохраненной фракцией выброса у пациентов старшего возраста. Клиническая геронтология. 2023;29(7-8):3-10 [Larina V.N., Oinotkinova O.Sh., Lunev V.I. Phenotypes of chronic heart failure with preserved ejection fraction in older patients. Clinical gerontology. 2023;29(7-8):3-10 (In Russian)]. DOI: 10.26347/1607-2499202307-08003-010

17. Хазова Е.В., Булашова О.В. Роль системного воспаления при сердечной не-достаточности. Казанский медицинский журнал. 2021;102(4):510-517 [Khazova E.V., Bulashova O.V. The role of systemic inflammation in heart failure. Kazansky Medical Journal. 2021;102(4):510-517 (In Russian)]. DOI: 10.17816/KMJ2021-510

18. Buleu F., Sirbu E., Caraba A. Heart Involvement in Inflammatory Rheumatic Dis-eases: A Systematic Literature Review. Medicina (Kaunas). 2019;55(6): 249. DOI: 10.3390/medicina55060249

19. Rich D.J., Burns J., Freed B.H. Meta-Analysis Global Group in Chronic (MAG-GIC) heart failure risk score: validation of a simple tool for the prediction of morbidi-ty and mortality in heart failure with preserved ejection fraction. J Am Heart Assoc. 2018;7(20):e009594. DOI: 10.1161/JAHA.118.009594

20. Wu C., Lv Z., Li X. Galectin-3 in Predicting Mortality of Heart Failure: A Sys-tematic Review and Meta-Analysis. Heart Surg Forum. 2021;24(2):E327-E332. DOI: 10.1532/hsf.3547